Tonix Pharmaceuticals Holding (TNXP) Retained Earnings (2010 - 2026)
Tonix Pharmaceuticals Holding's (TNXP) quarterly Retained Earnings came in at -$283000.0 in Q1 2026, down 6.39% year-on-year from -$302321.3 in Q1 2025, and up 99.97% quarter-over-quarter from -$854.7 million in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) Retained Earnings (2010 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's Retained Earnings history runs 17 years deep, the most recent figure standing at -$283000.0 for Q1 2026.
- On a quarterly basis, Retained Earnings fell 6.39% year-over-year to -$283000.0 in Q1 2026; TTM through Mar 2026 was -$283000.0, a 6.39% decrease from a year earlier, with the FY2025 full-year figure at -$854.7 million, down 335082.35% from the prior year.
- Retained Earnings improved to -$283000.0 in Q1 2026 per TNXP's latest filing, from -$854.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$118000.0 in Q1 2022 and bottomed at -$854.7 million in Q4 2025.
- The 5-year median for Retained Earnings is -$283000.0 (2026), against an average of -$283.5 million.
- Across the five-year window, Retained Earnings sank 541082.72% in 2022 and surged 99.96% in 2024, its largest moves.
- Year by year, Retained Earnings stood at -$167000.0 in 2022, then plunged by 359575.45% to -$600.7 million in 2023, then jumped by 99.96% to -$255000.0 in 2024, then plunged by 335082.35% to -$854.7 million in 2025, then soared by 99.97% to -$283000.0 in 2026.
- Per Business Quant, the three latest TNXP Retained Earnings figures stand at -$283000.0 (Q1 2026), -$854.7 million (Q4 2025), and -$807.8 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Tonix Pharmaceuticals Holding | 141.73 Mn | 141.73 Mn | 5.30 Mn | -283,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -283,000.00 |
| Dec 31, 2025 | -854.72 Mn |
| Sep 30, 2025 | -807.81 Mn |
| Jun 30, 2025 | -270,000.00 |
| Mar 31, 2025 | -266,000.00 |
| Dec 31, 2024 | -255,000.00 |
| Sep 30, 2024 | -250,000.00 |
| Jun 30, 2024 | -243,000.00 |
| Mar 31, 2024 | -615.60 Mn |
| Dec 31, 2023 | -600.66 Mn |
| Sep 30, 2023 | -573.34 Mn |
| Jun 30, 2023 | -212,000.00 |
| Mar 31, 2023 | -516.99 Mn |
| Dec 31, 2022 | -167,000.00 |
| Sep 30, 2022 | -438.36 Mn |
| Jun 30, 2022 | -409.38 Mn |
| Mar 31, 2022 | -118,000.00 |
| Dec 31, 2021 | -92,000.00 |
| Sep 30, 2021 | -81,000.00 |
| Jun 30, 2021 | -311.74 Mn |